论文部分内容阅读
目的:观察小剂量重组人红细胞生成素治疗恶性肿瘤相关性贫血的疗效。方法:100例恶性肿瘤相关贫血患者随机分为2组,治疗组(50例)给予重组人红细胞生成素6 000 u/次,1次/周,皮下注射,对照组(50例)给予重组人红细胞生成素150 u/(kg.次),3次/周,皮下注射。疗程均为8周。分别于治疗后4,8周评定疗效,并进行比较。结果:2组治疗后4,8周血红蛋白水平均较治疗前增高(P<0.05),2组治疗后血红蛋白水平、有效率比较差异无统计学意义(P>0.05);治疗组无明显不良反应,与对照组比较差异有统计学意义(P<0.05)。结论:小剂量重组人红细胞生成素治疗恶性肿瘤相关性贫血疗效满意且不良反应轻。
Objective: To observe the efficacy of low-dose recombinant human erythropoietin in the treatment of malignant tumor-associated anemia. Methods: One hundred patients with malignant tumor-associated anemia were randomly divided into two groups. The treatment group (50 cases) was given recombinant human erythropoietin (6 000 u / time, once a week, subcutaneous injection) and the control group (50 cases) Erythropoietin 150 u / (kg. Times), 3 times / week, subcutaneous injection. The course of treatment is 8 weeks. The curative effect was evaluated 4 and 8 weeks after treatment and compared. Results: After 4 and 8 weeks of treatment, hemoglobin levels in both groups were significantly higher than those before treatment (P <0.05). There was no significant difference in hemoglobin level and effective rate between the two groups after treatment (P> 0.05). There was no significant adverse reaction in the treatment group , Compared with the control group, the difference was statistically significant (P <0.05). Conclusion: The low dose recombinant human erythropoietin is effective in treating malignant tumor associated anemia with mild adverse reactions.